RR001

DRUG2 trials

Sponsors

Eir Biotherapies S.r.l., EIR Biotherapies s.r.l.

Conditions

Ductal adenocarcinoma of pancreasLocally Advanced Pancreatic AdenocarcinomaLocally advancednon-resectable pancreatic adenocarcinoma

Phase 1

RR001 in Combination with Chemotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma: Open-label, Non-randomized Dose Escalation Phase I/IIa Study

RecruitingCTIS2024-516019-26-00

Eir Biotherapies S.r.l.Ductal adenocarcinoma of pancreas, Locally advanced, non-resectable pancreatic adenocarcinoma

Start: 2025-06-25Target: 18Updated: 2025-12-09

Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

RecruitingNCT06861452

EIR Biotherapies s.r.l.Locally Advanced Pancreatic Adenocarcinoma

Start: 2025-06-25End: 2027-01-29Target: 9Updated: 2025-12-26